Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer.

Humans Austria Head and Neck Neoplasms / drug therapy Nivolumab Retrospective Studies Squamous Cell Carcinoma of Head and Neck / drug therapy
Head and neck cancer checkpoint inhibitor immunotherapy pembrolizumab real-world data

Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 05 01 2023
revised: 19 01 2023
accepted: 20 01 2023
entrez: 28 2 2023
pubmed: 1 3 2023
medline: 3 3 2023
Statut: ppublish

Résumé

Pembrolizumab alone or combined with chemotherapy is now approved in PD-L1-positive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Since real-world data are pending, our goal was to evaluate the efficacy and safety of immune checkpoint inhibitor (CPI) therapy in an unselected cohort of patients with SCCHN. We analyzed 78 patients with recurrent or metastatic SCCHN from three Austrian cancer centers that received CPI therapy alone or with chemotherapy as palliative first-line systemic treatment for this retrospective study. Patient characteristics, details on treatment, and survival were analyzed by a chart-based review. Of the 78 patients analyzed, 55 patients were treated with CPI alone (45 with Pembrolizumab, 10 with Nivolumab) and 23 patients received chemotherapy with a platinum and 5-FU in addition to CPI. With a median follow-up of twelve months, the median PFS of all patients was 4 months [95% confidence interval (CI)=2.2-5.8] and the median OS was 11 months (95% CI=7.1-14.9). The overall response and disease control rates were 20.5% and 46.1%, respectively. There was no statistically significant difference in clinical outcome between patient groups with a different combined positive score (CPS). The rate of reported immune related adverse events was comparable to existing data. Our findings confirm the results of the KEYNOTE-048 trial that CPI therapy alone or together with chemotherapy is an effective treatment for patients with recurrent or metastatic CPS-positive SCCHN.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Pembrolizumab alone or combined with chemotherapy is now approved in PD-L1-positive patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Since real-world data are pending, our goal was to evaluate the efficacy and safety of immune checkpoint inhibitor (CPI) therapy in an unselected cohort of patients with SCCHN.
PATIENTS AND METHODS METHODS
We analyzed 78 patients with recurrent or metastatic SCCHN from three Austrian cancer centers that received CPI therapy alone or with chemotherapy as palliative first-line systemic treatment for this retrospective study. Patient characteristics, details on treatment, and survival were analyzed by a chart-based review.
RESULTS RESULTS
Of the 78 patients analyzed, 55 patients were treated with CPI alone (45 with Pembrolizumab, 10 with Nivolumab) and 23 patients received chemotherapy with a platinum and 5-FU in addition to CPI. With a median follow-up of twelve months, the median PFS of all patients was 4 months [95% confidence interval (CI)=2.2-5.8] and the median OS was 11 months (95% CI=7.1-14.9). The overall response and disease control rates were 20.5% and 46.1%, respectively. There was no statistically significant difference in clinical outcome between patient groups with a different combined positive score (CPS). The rate of reported immune related adverse events was comparable to existing data.
CONCLUSION CONCLUSIONS
Our findings confirm the results of the KEYNOTE-048 trial that CPI therapy alone or together with chemotherapy is an effective treatment for patients with recurrent or metastatic CPS-positive SCCHN.

Identifiants

DOI: 10.21873/anticanres.16274 PMID: 36854497
pubmed: 36854497
pii: 43/3/1273
doi: 10.21873/anticanres.16274
doi:

Substances chimiques

Nivolumab 31YO63LBSN

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1273-1282

Informations de copyright

Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Sandro M Wagner (SM)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria.
Salzburg Cancer Research Institute, Salzburg, Austria.

Teresa Magnes (T)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria.
Salzburg Cancer Research Institute, Salzburg, Austria.

Thomas Melchardt (T)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria.
Salzburg Cancer Research Institute, Salzburg, Austria.

Dominik Kiem (D)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria.
Salzburg Cancer Research Institute, Salzburg, Austria.

Lukas Weiss (L)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria.
Salzburg Cancer Research Institute, Salzburg, Austria.

Daniel Neureiter (D)

Institute of Pathology, Paracelsus Medical University, Salzburg, Austria.

Christina Wagner (C)

Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Marie-Bernadette Aretin (MB)

Department of Pharmacy, Medical University of Vienna, Vienna, Austria.

Stefan Nemec (S)

Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.

Gabriele Gamerith (G)

Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria.

Georg Pall (G)

Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria.

Richard Greil (R)

III Medical Department at the Paracelsus Medical University, Salzburg, Austria; r.greil@salk.at.
Salzburg Cancer Research Institute, Salzburg, Austria.

Thorsten Fuereder (T)

Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Real-world Data of Palliative First-line...
questionsmedicales.fr › Régions géographiques › Europe › Autriche › Real-world Data of Palliative First-line...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Real-world Data of Palliative First-line...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Nivolumab › Real-world Data of Palliative First-line...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Real-world Data of Palliative First-line...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Real-world Data of Palliative First-line...